- Record: found
- Abstract: found
- Article: not found
Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age.
Philip Bejon
1 ,
John Lusingu ,
Ally Olotu ,
Amanda Leach ,
Marc Lievens ,
Johan Vekemans ,
Salum Mshamu ,
Trudie Lang ,
Jayne Gould ,
Marie-Claude Dubois ,
Marie-Ange Demoitié ,
Jean-Francois Stallaert ,
Preeti Vansadia ,
Terrell Carter ,
Patricia Njuguna ,
Ken O Awuondo ,
Anangisye Malabeja ,
Omar Abdul ,
Samwel Gesase ,
Neema Mturi ,
Chris J Drakeley ,
Barbara Savarese ,
Tonya Villafana ,
W Ripley Ballou ,
Joe Cohen ,
Eleanor M Riley ,
Martha M Lemnge ,
Kevin Marsh ,
Lorenz von Seidlein
Dec 11 2008
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Plasmodium falciparum malaria is a pressing global health problem. A previous study of the malaria vaccine RTS,S (which targets the circumsporozoite protein), given with an adjuvant system (AS02A), showed a 30% rate of protection against clinical malaria in children 1 to 4 years of age. We evaluated the efficacy of RTS,S given with a more immunogenic adjuvant system (AS01E) in children 5 to 17 months of age, a target population for vaccine licensure.